Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma. The main questions it aims to answer are:
* Is it safe when rh-endostatin and cisplatin are administered intra-arterially?
* Does intra-arterial cisplatin plus rh-endostatin increase the rate of tumor necrosis compared with traditional treatment?
Researchers will treat newly diagnosed osteosarcoma patients with systematic treatment and local treatment.
For systematic treatment, regular high-dose methotrexate and adriamycin will be administered intravenously.
For local treatment, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Local treatment is conducted by insertion of a catheter percutaneously using the Seldinger technique through the brachial or femoral artery under local anesthesia.
Participants will:
• Receive local combined with systematic treatment once every 2-3 weeks for 2-4 cycles before surgery.

Start Date01 Dec 2024

Sponsor / Collaborator-

NCT06618391

/ Not yet recruitingPhase 2IIT

Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC :a Prospective, Exploratory Phase II Clinical Study Tudy

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

Start Date08 Oct 2024

Sponsor / Collaborator

Henan Cancer Hospital

NCT06617936

/ RecruitingPhase 2IIT

Tislelizumab Combined With Recombinant Human Endostatin Injection Plus Chemotherapy in Unresectable Stage III NSCLC: a Prospective, Single-arm, Multicenter Phase II Clinical Study

This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus chemotherapy for stage III unresectable non-small cell lung cancer. To evaluate the surgical conversion rate of tirellizumab combined with recombinant human endostatin injection and chemotherapy induction therapy in patients with initially unresectable stage III non-small cell lung cancer.

Start Date27 Aug 2024

Sponsor / Collaborator

Shanghai Public Health Clinical Center

100 Clinical Results associated with Recombinant Human Endostatin (Simcere)

100 Translational Medicine associated with Recombinant Human Endostatin (Simcere)

100 Patents (Medical) associated with Recombinant Human Endostatin (Simcere)

503

Literatures (Medical) associated with Recombinant Human Endostatin (Simcere)

01 May 2025·LUNG CANCER

Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis

Review

Author: Pan, Yin ; Gu, Qiaohua

PURPOSE:

Brain metastases in non-small cell lung cancer (NSCLC) pose significant treatment challenges. This study aims to analyze whether the combination of targeted therapy and antiangiogenic therapy may bring greater clinical benefits.

METHODS:

We conducted a systematic review and meta-analysis of studies evaluating the efficacy and safety of targeted therapy combined with antiangiogenic therapy in patients with brain metastases from NSCLC. Pooled odds ratios (ORs) and hazard ratios (HRs) were calculated to determine the overall effect of combination therapy on clinical outcomes.

RESULTS:

Among the six included studies (n = 669), five studies used EGFR-TKI + Bevacizumab for combination therapy, and one study used EGFR-TKI + Endostar. Combination therapy significantly improved disease control rate (DCR) (OR = 3.98, 95 % CI: 2.56-6.18, p < 0.001) and response rate (RR) (OR = 6.63, 95 % CI: 2.89-15.22, p < 0.001) compared to controls. Progression-free survival (PFS) was markedly prolonged (HR = 0.52, 95 % CI: 0.39-0.69, p < 0.001), and overall survival (OS) improved significantly (HR = 5.75, 95 % CI: 3.22-10.29, p < 0.001). Subgroup analyses confirmed higher rates of hypertension and proteinuria when compared to targeted monotherapy (both p < 0.001). Other common adverse events showed no significant difference.

CONCLUSIONS:

Targeted therapy combined with anti-angiogenesis treatment significantly enhances clinical outcomes in NSCLC patients with brain metastases, including DCR, RR, PFS, and OS. Nonetheless, this combination increases the risk of adverse events, necessitating careful management.

01 Mar 2025·SUPPORTIVE CARE IN CANCER

Prognostic value of prognostic nutritional index in patients with nasopharyngeal carcinoma treated with endostar and concurrent chemoradiotherapy

Article

Author: Wen, YaJing ; Bie, Jun ; Song, JunMei ; Lv, YuQing ; Wang, RenSheng ; Huang, Qiulin ; Liu, Ting

PURPOSE:

This study aimed to evaluate the prognostic value of the pre-treatment prognostic nutritional index (PNI) in patients with locally advanced nasopharyngeal carcinoma (LANPC) treated with endostar combined with concurrent chemoradiotherapy (ECCRT).

METHODS:

Clinical data from 92 patients with LANPC who underwent ECCRT between May 2015 and December 2020 were retrospectively analyzed. The PNI was calculated using peripheral blood samples taken 1 week before treatment. The optimal cut-off value for PNI was determined via receiver operating characteristic (ROC) curve analysis based on overall survival (OS). Patients were categorized into high PNI and low PNI groups. The Kaplan-Meier method assessed the impact of PNI on survival, while univariate and multivariate Cox regression analyses identified independent risk factors affecting patient survival.

RESULTS:

The optimal cut-off value of PNI was 50.05. The 3-year OS, progression-free survival (PFS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRRFS) rates were 91.07% vs. 75.00% (P = 0.002), 83.93% vs. 66.67% (P = 0.015), 89.29% vs. 69.44% (P = 0.004), and 94.64% vs. 91.67% (P = 0.668) in the high PNI and low PNI groups, respectively. A low PNI was associated with shorter OS (HR = 3.592, P = 0.004), PFS (HR = 2.890, P = 0.017), and DMFS (HR = 3.826, P = 0.008). Multivariate analysis revealed that PNI was an independent prognostic factor for OS, PFS, and DMFS.

CONCLUSIONS:

The PNI may serve as a valuable prognostic predictor for patients with LANPC receiving ECCRT, aiding clinicians in selectively providing multimodal interventions to optimize survival outcomes.

01 Mar 2025·Environmental toxicology

RETRACTED: Poly (lactic‐co‐glycolic acid)‐encapsulated Endostar‐loaded calcium phosphate cement as anti‐tumor bone cement for the treatment of bone metastasis in lung cancer

Article

Author: Tian, QingHua ; Zhang, Kaixian ; Yan, BiCong ; Lu, YingYing ; Wu, ChunGen ; Tian, Cong

Abstract:

Lung cancer is one of the most common malignant tumors in the world. In approximately 30%–40% of lung cancer patients, bone metastases ensues with osteolytic destruction. Worse still, intractable pain, pathological fracture, and nerve compression caused by bone metastases are currently the bottleneck of research, diagnosis, and treatment of lung cancer. Therefore, the present study aims at investigating the effectiveness of a new composite material made of calcium phosphate cement (CPC) and Endostar on repairing bone defects in vitro and in vivo. As indicated in results, the mechanical properties of CPC+Endostar and CPC+PLGA+Endostar do not differ from those of pure CPC. The PLGA‐embedded Endostar slow‐release microspheres were designed and prepared, and were combined with CPC. Poly (lactic‐co‐glycolic acid (PLGA) is a biodegradable polymer material in vivo, so the effect on its mechanical properties is negligible. CPC+Endostar and CPC+PLGA+Endostar have been proved to inhibit cell proliferation, promote apoptosis and block cell cycle in G2 phase; the expression levels of osteoclast‐related genes CXCL2, TGF‐β1, IGF‐1, IL‐6, and RANKL were significantly decreased while osteogenic ability and alkaline phosphatase activity observably enhanced. In vivo studies have revealed that the expression levels of TRAP, RANKL, and Caspase3 in CPC+PLGA+ENDO‐treated tumor tissues after 3 weeks were higher than those in other groups with the prolongation of animal treatment time, while the expression levels of OPN and BCL2 were lower than those in other groups. In hematoxylin and eosin and TUNEL staining, 3 weeks of CPC+PLGA+ENDO‐treatment yielded higher tissue necrosis and apoptosis than other groups; computed tomography and magnetic resonance imaging results showed the posterior edge bone damage reduced as a result of the CPC+PLGA+ENDO grafting in vertebral pedicle. Overall, the feasibility and reliability of CPC‐loaded Endostar in the treatment of bone metastasis in lung cancer were investigated in this study, so as to promote the basic research and treatment of bone metastasis in lung cancer and other malignant tumors.

News (Medical) associated with Recombinant Human Endostatin (Simcere)

13 Jan 2025

·www.prnewswire.com

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. Continue Reading Cooperation of Simcere Zaiming and Abbvie SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma" "SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. " Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. SOURCE Simcere Zaiming WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inPhase 1ADC

13 Jan 2025

·www.prnewswire.com

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma" "SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. " Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory. About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. SOURCE AbbVie WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inPhase 1ADC

02 Sep 2024

·www.prnewswire.com

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate. According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China. These rights encompass but are not limited to marketing promotion, strategy formulation and adjustment, and the right to obtain relevant benefits from TGRX-326. TargetRx will receive an initial payment exceeding $20 million. Additionally, TargetRx will compensate Simcere Zaiming for promotional services. TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R. In preclinical studies and a Phase 1 clinical trial, TGRX-326 demonstrated robust anti-tumor activity and a favorable safety profile. Moreover, the molecule effectively crosses the blood-brain barrier, exhibiting exceptional efficacy in NSCLC patients with brain metastases. Dr. Renhong Tang, Chairman of Simcere Zaiming, said, "We are pleased to collaborate with TargetRx on novel dual-targeted therapy for lung cancer, a major malignancy that Simcere Zaiming strategically focuses on. This partnership will further enhance our innovative product portfolio. ALK/ROS1 fusion is a critical genetic mutation in non-small cell lung cancer. The advancement of targeted therapies has significantly improved survival rates for these patients. However, there remains a substantial need for new treatments with better efficacy and the ability to overcome drug resistance. We look forward to working closely with TargetRx to provide Chinese lung cancer patients with more effective treatment options as soon as possible." Dr. Yihan Wang, Chairman of TargetRx, said, "TGRX-326 is a potentially best-in-class novel anti-tumor molecule independently developed by TargetRx. It is a third-generation ALK inhibitor in late-stage clinical development which may bring a better option for patients. We believe that with the support of Simcere Zaiming, we will be able to bring this product quickly to the market. TargetRx aims to continuously deliver innovative therapies that will transform the lives of cancer patients." About Simcere Zaiming Simcere Zaiming, an oncology-centric biopharmaceutical subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), was established in 2023. The company is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several products in China, including COSELA®, Endostar®, Enweida®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners in cancer therapeutics. About TargetRx TargetRx is a clinical stage, high-tech pharmaceutical R&D company focused on developing next-generation targeted therapies for cancer patients, particularly those who are resistant or refractory to current treatments. TargetRx has developed a series of cutting-edge and efficient small molecule drug discovery platforms, which combine innovative research and development capabilities for drug design, screening, evaluation and optimization. Since its establishment, TargetRx has been granted over 170 patents from authorities in China, the US, Europe, Japan and other regions. Several potential best-in-class compounds are at different stages of multi-national clinical trials. SOURCE Simcere Pharmaceutical Group Limited

Phase 1License out/in

100 Deals associated with Recombinant Human Endostatin (Simcere)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	China	Shandong Simcere Biopharmaceutical Co. Ltd.	12 Sep 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malignant ascites	Phase 3	China	Shandong Simcere Biopharmaceutical Co. Ltd.	21 Jul 2021
Malignant Pleural Effusion	Phase 3	China	Shandong Simcere Biopharmaceutical Co. Ltd.	21 Jul 2021
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Aug 2018
Advanced Colorectal Adenocarcinoma	Phase 3	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Jul 2018
Advanced Lung Adenocarcinoma	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Mar 2012
Brain metastases	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Jun 2011
T-Cell Lymphoma	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Jun 2011
Esophageal Carcinoma	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 May 2011
Locally Advanced Melanoma	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Aug 2008
Metastatic melanoma	Phase 2	China	Jiangsu Simcere Pharmaceutical Co., Ltd.	01 Aug 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2024 Manual	Phase 2	Non-Small Cell Lung Cancer First line driver gene-negative	29	EnvafolimabRh-endostatin	yhyyrmeyrx(oyaymzrzsx) = kphfjrkftm fwqinujqow (ukbwfphrxs, 76.8 - 109.4) View more	Positive	09 Sep 2024
NCT05574998 (Pubmed)	Phase 2	Advanced Lung Non-Small Cell Carcinoma serum carcinoembryonic antigen (CEA)	48	rh-endostatin + platinum with pemetrexed	rpraoxaxbt(hfecxbohio) = vaqrxpzaui lzntrazjkm (jkjftnamoe, 3.8 - 9.1) View more	Positive	01 Jun 2024
				rh-endostatin + platinum with paclitaxel	rpraoxaxbt(hfecxbohio) = rzqxsvywby lzntrazjkm (jkjftnamoe, 3.8 - 9.1) View more
NCT02907710 (phase III, ASCO2024) Manual	Phase 3	Advanced Nasopharyngeal Carcinoma	300	Endostar plus CCRT	lnszkjwcis(lagroiwhcw) = hhgqzufhbq tereddcivj (tnodfoxcjx ) View more	Positive	24 May 2024
				CCRT alone	lnszkjwcis(lagroiwhcw) = bmgdhfijsh tereddcivj (tnodfoxcjx ) View more
ESMO_ASIA2023	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	90	Endostar plus concurrent chemoradiotherapy (CCRT)	djozlvnezy(mtscmbqmak) = bmgwazmhgw jrvysoavfn (rqxpcnpezv ) View more	Positive	02 Dec 2023
				Concurrent chemoradiotherapy (CCRT)	rbbculbjzv(iizbygugdg) = ywtjklqriv txycrjajwx (jqwvuzachx ) View more
ESMO 12023 \| ESMO 22023 Manual	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	92	Endostar+concurrent chemoradiotherapy	ghtcgqegss(fiwzyybenc) = ynqroxnsaq lacexpihid (njnxwxjavf ) View more	Positive	23 Oct 2023
				Concurrent chemoradiotherapy	ghtcgqegss(fiwzyybenc) = xrduffjpdx lacexpihid (njnxwxjavf ) View more
ESMO_GCC2023	Not Applicable	Locally Advanced Cervical Carcinoma	41	Endostar combined with chemoradiotherapy	qbpotdlpaq(feuadobjhi) = fwidoxmagf zubmlmpkdx (ikxbrdlsrw ) View more	-	23 Feb 2023
				Chemoradiotherapy	qbpotdlpaq(feuadobjhi) = urdinryxtv zubmlmpkdx (ikxbrdlsrw ) View more
CSCO2022	Not Applicable	Lung Cancer \| Malignant Pleural Effusion	78	顺铂	sgzkeeclxh(ajcakooqhg) = jrhzsuympn wdliixxwhx (yhnvhhihaz ) View more	-	21 Sep 2022
CSCO2022	Not Applicable	Advanced Lung Squamous Cell Carcinoma	19	重组人血管内皮抑制素联合阿法替尼及替吉奥	hizajmbsxq(epuykdaigb) = 没有与治疗相关的死亡报告 qpskbjxgrc (tfzkbvdzur ) View more	-	21 Sep 2022
CSCO2022	Not Applicable	-	815	对照治疗组	htgaugqsco(wfccurpakv) = tmpreyejgj cjkdxjihzs (pvcunhcxhw ) View more	Positive	21 Sep 2022
				恩度治疗组	htgaugqsco(wfccurpakv) = ztlpxswpft cjkdxjihzs (pvcunhcxhw ) View more
WCLC2022	Not Applicable	Advanced Lung Non-Small Cell Carcinoma	27	Endostar + Camrelizumab + Chemotherapy	lhfvrrnxge(xlvwkxwzek) = zeqzjftxgt gjglnxhebx (hlfktyrdjt ) View more	-	06 Aug 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis